Seven Eight Capital’s Cytokinetics CYTK Stock Holding History

Seven Eight Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,935	Closed	-$486K	–	740
2024 Q1	$486K	Sell	6,935 -55,294	-89%	-$4.28M	0.05%	458
2023 Q4	$5.2M	Buy	+62,229	New	+$2.25M	0.6%	41
2023 Q2	–	Sell	-9,443	Closed	-$332K	–	535
2023 Q1	$332K	Buy	+9,443	New	+$385K	0.07%	315
2022 Q4	–	Sell	-7,907	Closed	-$383K	–	458
2022 Q3	$383K	Sell	7,907 -12,920	-62%	-$622K	0.08%	326
2022 Q2	$818K	Buy	+20,827	New	+$838K	0.33%	108
2022 Q1	–	Sell	-8,979	Closed	-$409K	–	559
2021 Q4	$409K	Buy	8,979 +1,279	+17%	+$49.4K	0.07%	304
2021 Q3	$275K	Buy	+7,700	New	+$227K	0.03%	507
2020 Q4	–	Sell	-28,800	Closed	-$624K	–	452
2020 Q3	$624K	Buy	+28,800	New	+$674K	0.13%	292

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Seven Eight Capital's CYTK Position: Q2 2024 in Review

Seven Eight Capital sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 6,935 shares — an estimated $486K sold.

Seven Eight Capital first reported a position in CYTK in Q3 2020 and held it in 8 quarters. The position peaked at $5.2M in Q4 2023. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

Seven Eight Capital reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
Seven Eight Capital sold 6,935 Cytokinetics shares in Q2 2024, an estimated $486K.
Seven Eight Capital first reported a position in Cytokinetics in Q3 2020 and held it in 8 quarters.
Seven Eight Capital's Cytokinetics position peaked at $5.2M in Q4 2023.
343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.